Feb 14, 2024 / 08:30AM GMT
Operator
Welcome to BioArctic Q4 report 2023 for the first part of the conference call. (Operator Instructions) Now I will hand the conference over to CEO, Gunilla Osswald; and CFO, Anders Martin-Löf, please go ahead.
Gunilla Osswald - BioArctic AB(publ)-CEO
Good morning, and welcome to buy BioArctic presentation for the fourth quarter and for the full year of 2023 I'm Gunilla Osswald and I'm CEO of BioArctic, and I will share today's presentation with our CFO, Anders Martin-Löf.
It's very exciting times to BioArctic with lecanemab being the first and only disease-modifying treatment with a full approval in the US and Japan and now also in China, it's the beginning of a new era and BioArctic is behind this true breakthrough in the treatment of Alzheimer's disease. I find it extremely gratifying that we now can help a large number of patients and their families, and I'll talk more about that here today.
Next slide, please. BioArctic is listed at Nasdaq, Stockholm, Large-Cap, and this is our disclaimer.
Next
Q4 2023 BioArctic AB Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
